Holen Sie sich die Stockscreener-App
7.51
8.85%
-0.51
Schlusskurs vom Vortag:
$8.02
Offen:
$7.9
24-Stunden-Volumen:
48,201
Relative Volume:
1.23
Marktkapitalisierung:
$71.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-129.41M
KGV:
-0.3117
EPS:
-24.0922
Netto-Cashflow:
$-51.97M
1W Leistung:
-4.69%
1M Leistung:
-4.82%
6M Leistung:
+18.48%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.60
$8.195
1-Wochen-Bereich:
$7.43
$8.27
52-Wochen-Spanne:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Firmenname
Leonabio Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
7.60 | 75.56M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Leonabio Inc Aktie (LONA) Neueste Nachrichten
A drug developer's New York fireside chat is set for Sept. 11 - Stock Titan
Perceptive Advisors LLC Expands LeonaBio Inc (LONA) Stake in Str - GuruFocus
Sermonix Pharmaceuticals Discloses Investment at LeonaBio, Inc. with 36.9% Stake - TradingView
Prefunded warrants drive Sermonix-led LeonaBio (LONA) share shakeup - Stock Titan
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
LeonaBio Reaches Key Phase 3 Enrollment Milestone - TipRanks
Perceptive's LeonaBio (NASDAQ: LONA) stake nears its ownership limit - Stock Titan
Anders Hove reports new passive stake in LeonaBio (LONA) - Stock Titan
LONA Maintained by Mizuho -- Price Target Lowered to $15.00 - GuruFocus
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Nigeria
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), LeonaBio (LONA) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LeonaBio Reports Narrower Quarter Loss as Trial Progresses - sekbernews.id
LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming Milestones - Pulse 2.0
LeonaBio (LONA) Market Close: Closes 3.19% Higher at $7.96 at the Close; Level Check: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotLow Volatility Picks - vinanet.vn
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceWedge Breakout - Vinanet
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - Kalkine
LONA Maintained by Citizens -- Price Target Lowered to $17.00 - GuruFocus
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances - Yahoo Finance
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Nigeria
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio - GuruFocus
Citizens lowers LeonaBio stock price target to $17 on valuation By Investing.com - Investing.com Canada
LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade
LeonaBio Narrows Q2 Loss - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan
LeonaBio Q2 net loss widens on higher R&D spending - TradingView
LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative
LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LeonaBio’s lasofoxifene to be featured at breast cancer summit By Investing.com - Investing.com Nigeria
LeonaBio’s lasofoxifene to be featured at breast cancer summit - Investing.com
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer - The Manila Times
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), - GlobeNewswire
LONA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares RisePost-Earnings Reaction - vinanet.vn
LONA Q1 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineEPS Growth Report - vinanet.vn
LONA: LeonaBio, Inc.12 Month EPS - Zacks Investment Research
LeonaBio Inc. (LONA) Slips 2.74% to $7.45 as Biotech Stock Nears Key SupportDividend ETF - vinanet.vn
LeonaBio Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-than-Expected Loss Driven by Expense ManagementRevenue Estimate Trend - vinanet.vn
LeonaBio Inc. (LONA) Advances 2.08%: Biotech Stock Tests Mid-Range Resistance After Oversold BounceBreakaway Gap - dars.gov.et
LONA|LeonaBio Ord Shs|Price:7.275|Chg%:-0.115 - TradingKey
LeonaBio Ord Shs (LONA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LeonaBio Ord Shs (LONA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LeonaBio, Inc. Revenue Breakdown – NASDAQ:LONA - TradingView
LeonaBio Ord Shs (LONA) Institutional Confidence - TradingKey
LONA Q1 2026 Earnings: EPS Surprises to the Upside as Biotech Advances PipelineBook Value Growth - vinanet.vn
LONA Q1 2026 Earnings: Narrowed Loss Exceeds Expectations, Stock Rises 5.7%Consensus Miss Rate - vinanet.vn
LONA Q1 2026 Earnings: EPS Beat Drives 4.85% Stock Surge Despite Zero RevenueNon-GAAP Earnings - vinanet.vn
Finanzdaten der Leonabio Inc-Aktie (LONA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Leonabio Inc-Aktie (LONA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):